Medication Responsiveness of Motor Symptoms in a Population-Based Study of Parkinson Disease

被引:20
作者
Bordelon, Yvette M. [1 ]
Hays, Ron D. [2 ,3 ,4 ]
Vassar, Stefanie D. [1 ,5 ]
Diaz, Natalie [6 ]
Bronstein, Jeff [1 ,5 ]
Vickrey, Barbara G. [1 ,5 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90095 USA
[4] RAND Corp, Santa Monica, CA 90407 USA
[5] Parkinsons Dis Res, VA Greater Los Angeles Healthcare Syst, Educ & Clin Ctr, Los Angeles, CA 90073 USA
[6] Harbor UCLA Med Ctr, Dept Neurol, Torrance, CA 90502 USA
基金
美国国家卫生研究院;
关键词
LEVODOPA; PROGRESSION;
D O I
10.4061/2011/967839
中图分类号
R74 [神经病学与精神病学];
学科分类号
100204 [神经病学];
摘要
We assessed degree of Parkinson disease motor symptom improvement with medication among subjects enrolled in an ongoing, population-based study in Central California. The motor section of the unified Parkinson disease rating scale (UPDRS) was performed on subjects in both OFF and ON medication states, and difference between these scores was used as an indicator of symptomatic benefit. Higher OFF minus ON scores correlated with more severe baseline symptoms. There was equivalent improvement on the motor UPDRS scale for subjects divided according to medication classes used: levodopa alone 7.3 points, levodopa plus other medications 8.5 points, and dopamine agonists but not levodopa 6.1 points. In addition, there was no difference in the magnitude of improvement when subjects were divided according to Parkinson disease subtype, defined as tremor dominant, akinetic-rigid, or mixed. In this community-based sample, these values are within the range of a clinically important difference as defined by previous studies.
引用
收藏
页数:6
相关论文
共 12 条
[1]
Fahn S, 2004, NEW ENGL J MED, V351, P2498
[2]
Fahn S.E., 1987, UNIFIED PARKINSONS D
[3]
Holloway RG, 2004, ARCH NEUROL-CHICAGO, V61, P1044
[4]
Benign tremulous Parkinsonism [J].
Josephs, KA ;
Matsumoto, JY ;
Ahlskog, JE .
ARCHIVES OF NEUROLOGY, 2006, 63 (03) :354-357
[5]
Clinical characteristics in early Parkinson's disease in a Central California population-based study [J].
Kang, GA ;
Bronstein, JM ;
Masterman, DL ;
Redelings, M ;
Crum, JA ;
Ritz, B .
MOVEMENT DISORDERS, 2005, 20 (09) :1133-1142
[6]
Pharmacotherapy of Parkinson's disease in Germany [J].
Möller, JC ;
Körner, Y ;
Dodel, R ;
Meindorfner, C ;
Stiasny-Kolster, K ;
Spottke, A ;
Krüger, HP ;
Oertel, W .
JOURNAL OF NEUROLOGY, 2005, 252 (08) :926-935
[7]
LEVODOPA PHARMACOKINETICS AND PHARMACODYNAMICS IN FLUCTUATING PARKINSONIAN-PATIENTS [J].
NUTT, JG ;
WOODWARD, WR .
NEUROLOGY, 1986, 36 (06) :739-744
[8]
Course in Parkinson disease subtypes A 39-year clinicopathologic study [J].
Rajput, A. H. ;
Voll, A. ;
Rajput, M. L. ;
Robinson, C. A. ;
Rajput, A. .
NEUROLOGY, 2009, 73 (03) :206-212
[9]
Dyskinesias and motor fluctuations in Parkinson's disease - A community-based study [J].
Schrag, A ;
Quinn, N .
BRAIN, 2000, 123 :2297-2305
[10]
Minimal clinically important change on the Unified Parkinson's Disease Rating Scale [J].
Schrag, Anette ;
Sampaio, Cristina ;
Counsell, Nicholas ;
Poewe, Werner .
MOVEMENT DISORDERS, 2006, 21 (08) :1200-1207